Why the study?
Does sacubitril/valsartan reduce NT-proBNP compared to valsartan in patients with heart failure with preserved ejection fraction?
Does sacubitril/valsartan reduce NT-proBNP compared to valsartan in patients with heart failure with preserved ejection fraction?
Sacubitril/valsartan consistently reduces the biomarker NT-proBNP in patients with HFpEF, regardless of sex or baseline ejection fraction.
Supports broad sacubitril/valsartan use in HFpEF; extends evidence across sex and EF subgroups.
Baseline NT-proBNP predicted HF events but did not modify the sacubitril/valsartan treatment effect in patients with HFpEF. Sacubitril/valsartan reduced NT-proBNP consistently in men and women, and in patients with lower or higher EF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).
No takes yet. Share an insight, caveat, or question.
Cunningham et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: